

The need to research refractory breathlessness.

Currow DC, Abernethy AP, Allcroft P, Banzett RB, Bausewein C, Booth S, Carrieri-Kohlman V, Davidson P, Disler R, Donesky D, Dudgeon D, Ekstrom M, Farquhar M, Higginson I, Janssen D, Jensen D, Jolley C, Krajnik M, Laveneziana P, McDonald C, Maddocks M, Morelot-Panzini C, Moxham J, Mularski RA, Noble S, O'Donnell D, Parshall MB, Pattinson K, Phillips J, Ross J, Schwartzstein RM, Similowski T, Simon ST, Smith T, Wells A, Yates P, Yorke J, Johnson MJ.

Eur Respir J. 2016 Jan;47(1):342-3. doi: 10.1183/13993003.00653-2015.
PubMed PMID: 26721965.

The joint ATS / ERS statement ‘An official American Thoracic Society / European Respiratory Society statement: research questions in COPD’ by Celli et al is a timely summary of current evidence and the questions that arise directly from where that evidence reaches its limits. Such documents are crucial in framing research strategies for researchers and research funders.

Daily breathlessness at rest or on minimal exertion is experienced by many of the 330 million people globally living with COPD. It is a debilitating and burdensome symptom, experienced for long periods of time not just in the last weeks or months of life. This occurs despite inhaled treatments prescribed to reduce breathlessness: their failure to fully relieve breathlessness may add to patients’ despair and, at the very time when more support is needed, doctors often turn away. The majority of people with COPD will have a prolonged period of life with such severe breathlessness. The ATS / ERS’ statement signals the need for research into:

- methods of alleviating breathlessness by modifying the underlying disease course;
- pulmonary rehabilitation; and
- symptom control and advance planning during the terminal stages of the disease.

While these are important goals and the document flags symptom control as important (and laudably notes that pulmonary function tests and imaging are surrogates for assessing breathlessness), the statement ignores the pressing need for research that ensures relief of breathlessness for the prolonged duration when COPD is already maximally treated; this seems a significant omission.

This burden of breathlessness in COPD starts well before the “end of life” for most people.(1) Palliating chronic refractory breathlessness must be an ongoing focus for research if we are to make a difference to the lives of these tens of millions of people now and into the future.(2) Even if a treatment were to be found today that could cure or prevent COPD, there is a generation of people who experience breathlessness as a daily challenge that deserve the combined intellectual expertise of the global research community.

The inclusion of ways to treat chronic refractory breathlessness in optimally treated COPD more effectively is a worthy research goal, building on the emerging evidence of the mechanisms and management of breathlessness. Managing breathlessness has the potential to improve markedly peoples’ function for day-to-day activities such as self-care and ensure that they are more comfortable, even when the underlying cause(s) of their breathlessness cannot be reversed or stabilised. Level 1 efficacy evidence (meta-analyses), which needs to be confirmed by adequately powered trials, already identifies an important role for non-pharmacological interventions, oxygen and regular, low-dose morphine in reducing

breathlessness in this population.(3-8) A research program also needs to include subsequent effectiveness studies. The recognition that breathlessness is truly multi-dimensional and that modification of its affective component into account can bring significant clinical benefits even in the absence of measurable pathophysiological changes, also opens new avenues for research.

There is an urgently needed research agenda which aims to improve the quality of life for people with chronic refractory breathlessness caused by progressive COPD. Routine assessment of breathlessness and its impact on the person's quality of life followed by evidence-based management of refractory breathlessness can be seen as a fundamental human right, and is an urgent priority for researchers and funders alike.(9;10)

Reference List

- (1) Bausewein C, Booth S, Gysels M, Kuhnbach R, Haberland B, Higginson IJ. Understanding breathlessness: cross-sectional comparison of symptom burden and palliative care needs in chronic obstructive pulmonary disease and cancer. *J Palliat Med* 2010 Sep;13(9):1109-18.
- (2) Johnson MJ, Currow DC, Booth S. Prevalence and assessment of breathlessness in the clinical setting. *Expert Rev Respir Med* 2014 Apr;8(2):151-61.
- (3) Bausewein C, Booth S, Gysels M, Higginson I. Non-pharmacological interventions for breathlessness in advanced stages of malignant and non-malignant diseases. *Cochrane Database Syst Rev* 2008;(2):CD005623.
- (4) Abernethy AP, Currow DC, Frith P, Fazekas BS, McHugh A, Bui C. Randomised, double blind, placebo controlled crossover trial of sustained release morphine for the management of refractory dyspnoea. *BMJ* 2003 Sep 6;327(7414):523-8.
- (5) Johnson MJ, Bland JM, Oxberry SG, Abernethy AP, Currow DC. Opioids for chronic refractory breathlessness: patient predictors of beneficial response. *Eur Respir J* 2013 Sep;42(3):758-66.
- (6) Abernethy AP, McDonald CF, Frith PA, Clark K, Herndon JE, Marcello J, et al. Effect of palliative oxygen versus room air in relief of breathlessness in patients with refractory dyspnoea: a double-blind, randomised controlled trial. *Lancet* 2010 Sep 4;376(9743):784-93.
- (7) Uronis HE, Ekstrom MP, Currow DC, McCrory DC, Samsa GP, Abernethy AP. Oxygen for relief of dyspnoea in people with chronic obstructive pulmonary disease who would not qualify for home oxygen: a systematic review and meta-analysis. *Thorax* 2014 Dec 3.
- (8) Jennings AL, Davies AN, Higgins JP, Gibbs JS, Broadley KE. A systematic review of the use of opioids in the management of dyspnoea. *Thorax* 2002 Nov;57(11):939-44.
- (9) Currow DC, Johnson MJ. The essence of breathlessness - the first vital symptom. *European Respiratory Journal* 2015; *in press*.
- (10) Currow DC, Abernethy AP, Ko DN. The active identification and management of chronic refractory breathlessness is a human right. *Thorax* 2014 Apr;69(4):393-4.